However, pemetrexed‐based regimen has been inferior to nonpemetrexed‐based chemotherapy in lung adenocarcinoma patients with negative TTF‐1 expression in terms of PFS and OS.16 This evidence concerns the gene TTF1 and lung adenocarcinoma.